Diabetes Market Forecast to 2013

Published by: Cutting Edge Information

Published: Jan. 1, 2009 - 258 Pages

Table of Contents

Type I Antidiabetic Treatments

Traditional Insulins

Novolin

Humulin

Short-Acting Insulin Analogs

Novolog

Humalog

Apidra

Long-Acting Insulin Analogs

Levemir

Lantus

Other Drugs

Symlin

Technosphere

Teplizumab

Otelixuzumab

TT-223

Type II Antidiabetic Treatments

DPP-4 Inhibitors

Januvia (includes Janumet)

Galvus (includes Eucreas)

Alogliptin

Onglyza

GLP-1 Analogs

Byetta (includes Byetta Long-Acting Release)

Liraglutide

AVE0010

Syncria

Tapsoglutide

SGLT-2 Inhibitors

AVE2268

Remogliflozin

Dapagliflozin

Sulfonylureas

Amaryl

Glucotrol

Thiazolidinediones (TZDs)

Avandia (includes Avandamet and Avandaryl)

Actos (includes Actoplus Met and Duetact)

Meglitinides

Prandin

Starlix

Glufast

Alpha-Glucosidase Inhibitors

Precose

Glyset

Other

Acomplia

MBX-102

AGI-1067

XOMA052

SRT501

MB07803

ISIS113715

Adjunct Therapies

Cymbalta

Arxxant

Avapro

Cozaar

Lyrica

Zyvox

Regranex

Lucentis

Atacand

Epicept NP-1

Qnexa

PRODUCT PROFILE COMPONENTS

Drug’s development and approval history

Competitive and strategic positioning

Current status of drug, including approval history

Current and projected competitive strengths/vulnerabilities

Current and projected sales position within class

Market growth opportunities

Analysis combines current sales, market landscape and/or clinical trial info with projections and predicted market events

Sales projection charts for next 4-7 years

Materiality charts (drug's percentage of company revenue) for 2007 and 2012

Patents and generics charts containing market exclusivity and patent information for approved drugs

Clinical trial data tables

Summary of most important trials

Trial title and objective

Start and end dates

Abstract

Comprehensive Diabetes Forecast

Which companies are poised to dominate the diabetes market? With new classes on the rise, which innovative therapies will make an impact? How will clinical results and safety issues affect drug profitability over the long term?

CEI’s veteran analysts answer these questions — and more — by placing critical drug information in a relevant industry-wide context. Other reports skim the surface, examining only top drugs at top companies. Ours is complete, covering marketed brands, pipeline products, clinical development, whole drug classes and top drug manufacturers — all in one, easy-to-read format.

From showing the most accurate sales projections and pipelines to identifying market threats and opportunities, “Diabetes Market Forecast to 2013” provides teams with a hard-hitting, penetrating analysis of the global diabetes market. For reliable evidence to support key resource allocation decisions, this is the only resource you’ll need.

Give your brand team all the diabetes data it needs to make critical product decisions!

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.